Confo Therapeutics
Manuela Rinaldi is a highly experienced Principal Scientist in Pharmacology at Confo Therapeutics, with prior roles including Senior Scientist in Preclinical Operations at ExeVir and Senior Project Manager in Life Sciences at Modis, where involvement in multistakeholder collaborations and EU-funded projects was prominent. Rinaldi's background also includes substantial contributions as a Scientist in Pharmacology, Pharmacodynamics, and Translational Medicine at Ablynx, overseeing teams and managing collaborations with Contract Research Organizations (CROs). Rinaldi holds a PhD in Medical Sciences from KU Leuven, focusing on emphysema models related to Chronic Obstructive Pulmonary Disease (COPD), and an extensive academic foundation with a Master's degree in Biomedical Sciences.
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.